Pages that link to "Q33362177"

The following pages link to Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study (Q33362177):

Displayed 24 items.

• The predictability of claim-data-based comorbidity-adjusted models could be improved by using medication data (Q30698080) ‎ (← links)
• A Severe Sepsis Mortality Prediction Model and Score for Use With Administrative Data (Q30700423) ‎ (← links)
• A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data (Q30713544) ‎ (← links)
• Comparative effectiveness research with administrative health data in rheumatoid arthritis (Q31077662) ‎ (← links)
• Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis (Q33648507) ‎ (← links)
• Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity (Q33651231) ‎ (← links)
• Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis (Q33691553) ‎ (← links)
• The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents (Q35082559) ‎ (← links)
• An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. (Q35381990) ‎ (← links)
• A comparison of stroke severity proxy measures for claims data research: a population-based cohort study (Q35876282) ‎ (← links)
• The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease (Q35904678) ‎ (← links)
• Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study (Q35910779) ‎ (← links)
• Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic (Q36942874) ‎ (← links)
• Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic (Q36942952) ‎ (← links)
• Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study (Q38937245) ‎ (← links)
• TIM-1 rs41297579 G>A (-1454) and TIM-4 rs7700944 gene polymorphisms as possible risk factor for rheumatoid arthritis: relation to activity and severity. (Q39272815) ‎ (← links)
• Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis (Q46337002) ‎ (← links)
• Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. (Q46460604) ‎ (← links)
• Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. (Q53119214) ‎ (← links)
• Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab (Q61448032) ‎ (← links)
• Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study (Q90665225) ‎ (← links)
• Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases (Q92085802) ‎ (← links)
• Extraction of Rheumatoid Arthritis Disease Activity Measures From Electronic Health Records Using Automated Processing Algorithms (Q92224140) ‎ (← links)
• The impact of rehabilitation frequency on the risk of stroke in patients with rheumatoid arthritis (Q92590106) ‎ (← links)